Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

Heikki Joensuu(University of Helsinki), Johan Lundin(University of Helsinki), Vesa Kataja(South Eastern Finland University of Applied Sciences), Tiina Salminen, Jorma Isola(Tampere University Hospital), Karl von Smitten(Helsinki University Hospital), Mikael Lundin(University of Helsinki), Taina Turpeenniemi‐Hujanen(Oulu University Hospital), Kaija Holli(Tampere University Hospital), Liisa Pylkkänen
PubMed
March 1, 2003
Cited by 209

Related Papers

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k